Q2 2026 saw a 10.7% sales decline due to distributor inventory effects, but underlying demand and direct sales remain strong. Gross margin was impacted by a one-off, while cost control and cash flow improved. The CyberGene acquisition and new product launches strengthen the outlook.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.